Literature DB >> 17430692

Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors.

Daniel P Petrylak1.   

Abstract

Entities:  

Year:  2007        PMID： 17430692     DOI： 10.1007/s11912-007-0023-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  6 in total

Review 1.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

Review 2.  Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.

Authors:  Michael A Carducci; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

3.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

4.  Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

Authors:  Michael A Carducci; Joel B Nelson; M Kathy Bowling; Theresa Rogers; Mario A Eisenberger; Victoria Sinibaldi; Ross Donehower; Terri L Leahy; Robert A Carr; Jeffrey D Isaacson; Todd J Janus; Amy Andre; Balakrishna S Hosmane; Robert J Padley
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.